Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance's Oxygent back on track for cardiac surgery:

This article was originally published in Clinica

Executive Summary

Following a setback in January, Alliance Pharmaceutical is once again pushing ahead with plans to develop its oxygen-carrying therapeutic, Oxygent, for use during cardiac surgery. The company had suspended enrolment in a phase III trial of the product in heart bypass procedures after observing an unexpected difference in the incidence of adverse events (AEs) between the treated patients and controls (see Clinica No 942, p 19). A preliminary analysis of the safety data has failed to find evidence to link the product directly to imbalance in AEs, says the San Diego, California company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel